Patents Assigned to ARTAX BIOPHARMA INC.
  • Chromene derivatives as inhibitors of TCR-Nck interaction
    Patent number: 11807633
    Abstract: The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: November 7, 2023
    Assignee: Artax Biopharma Inc.
    Inventors: Julio Castro, Andrés Gagete Mateos, Peter J. Machin, Christopher Loren Vandeusen
  • Aryl-piperidine derivatives
    Patent number: 11505526
    Abstract: An aryl-piperidine derivative of formula I, wherein the meaning of R3, X, Cz, and Cy is that specified in the description, for use as inhibitors of T cells.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: November 22, 2022
    Assignee: Artax Biopharma Inc.
    Inventors: Andrés Gagete Mateos, Damiá Tormo Carulla, Luc Marti Clauzel, Julio Castro Palomino
  • Aza-dihydro-acridone derivatives
    Patent number: 11434239
    Abstract: Aza-dihydro-acridone derivatives of formula I, wherein the meaning of R1, R?1, R2 and R3 is that specified in the description, to be used as T cells proliferation inhibitors.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: September 6, 2022
    Assignee: Artax Biopharma Inc.
    Inventors: Andrés Gagete Mateos, Damiá Tormo Carulla, Luc Marti Clauzel, Julio Castro Palomino
  • Chromene derivatives as inhibitors of TCR-Nck interaction
    Patent number: 11008310
    Abstract: The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: May 18, 2021
    Assignee: Artax Biopharma Inc.
    Inventors: Julio Castro, Andrés Gagete Mateos, Peter J. Machin, Christopher Loren Vandeusen
  • Chromene derivatives as inhibitors of TCR-NCK interaction
    Patent number: 10696663
    Abstract: The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 30, 2020
    Assignee: Artax Biopharma Inc.
    Inventors: Julio Castro, Andrés Gagete Mateos, Peter J. Machin, Christopher Loren VanDeusen
  • Chromene derivatives as inhibitors of TCR-Nck interaction
    Patent number: 10106518
    Abstract: The present invention relates to a group of compounds of formula (I) containing a chromene nucleus: and which present the ability to inhibit the lymphocytes proliferation mediated by the TCR interaction with Nck, so that the present invention also relates to the use of these compounds for the treatment of diseases or conditions wherein said interaction triggers a complication such as transplant rejection reactions, immune or autoimmune diseases, inflammatory diseases or proliferative diseases.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: October 23, 2018
    Assignee: Artax Biopharma Inc.
    Inventors: Andrés Gagete Mateos, Julio Castro Palomino, Luc Marti Clauzel, Damiá Tormo Carulla
  • CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION
    Publication number: 20160244423
    Abstract: The present invention relates to a group of compounds of formula (I) containing a chromene nucleus: and that present the capacity to inhibit the proliferation of lymphocytes mediated by the Nck interaction with TCR, so that the present invention also relates to the use of these compounds for the treatment of diseases or conditions where said interaction triggers a complication such as transplant rejection reactions, immune or autoimmune diseases, inflammatory diseases or proliferative diseases.
    Type: Application
    Filed: October 20, 2014
    Publication date: August 25, 2016
    Applicant: ARTAX BIOPHARMA INC.
    Inventors: Andrés Gagete Mateos, Julio Castro Palomino, Luc Marti Clauzel, Damiá Tormo Carulla